Business Wire

Business Wire is the global leader in news release distribution and regulatory disclosure. Business Wire delivers news and multimedia directly into editorial systems and leading online news platforms and is a trusted source for news organisations, journalists, investment professionals and regulatory authorities.

Results: 469-480 of 11976

Upstream Festival The Netherlands 2025: Everything Startups and Scale-Ups Need to Grow

ABEC Unveils Breakthrough Single Use Bioreactor Technology for Cell Therapy Manufacturing

David Ferrando, Ferrer's Chief Marketing and Market Access Officer and Jorge Cuneo, Ferrer's Chief Medical Officer, at the IMPAHCT opening session.

Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management

ROYC and BCG: Capturing Wealth Management’s $3 Trillion Private Market Opportunity

ICON plc Schedules First Quarter 2025 Earnings Conference Call

Pulsant to Acquire Two Data Centres From SCC

In 2008, GN Corp initiated research with NCRM, Chennai, Tamil Nadu, India on restoring corneal blindness using buccal tissue epithelial cells. An out of the box idea of Dr. Suryaprakash, Urologist from Hyderabad, India in 2012 to apply buccal (oral) mucosal cells to repair stricture-inflicted male urethra, led to a clinical study, which he presented in NCRM NICHE 2017 in Tokyo, kickstarting a collaboration with Dr. Akio Horiguchi, National Defence Medical College, Japan, as they met in EAU in 2018 (Top right picture). Upon confirming successful cell engraftment in urethral stricture pre-clinical models taking help from the Dept. of Medical Engineering of NDMC between 2018~2023, (Bottom, right picture), now in 2025, clinical application has been initiated in Edogawa Hospital, Tokyo. Main picture: BEES-HAUS team after the first clinical transplant in Edogawa Hospital, Tokyo; Dr.Horiguchi (Centre) with Dr.Shojiro Katoh (President, Edogawa Hospital) standing left to him.

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Richard Stevenson, Chief Executive Officer of Cleverbridge

Business Wire

Upstream Festival The Netherlands 2025: Everything Startups and Scale-Ups Need to Grow

ABEC Unveils Breakthrough Single Use Bioreactor Technology for Cell Therapy Manufacturing

Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management

ROYC and BCG: Capturing Wealth Management’s $3 Trillion Private Market Opportunity

ICON plc Schedules First Quarter 2025 Earnings Conference Call

Pulsant to Acquire Two Data Centres From SCC

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Cleverbridge Announces Leadership Transition

KBRA Releases Research – AI Adoption and European Sovereign Credit Analysis

LTIMindtree Announces Strategic Partnership with Google Cloud to drive Business Transformation with Agentic AI

Ideagen shines in G2 Spring 2025 Reports with 82 badges and 31 top rankings